Repository logo
 

Myeloproliferative neoplasms: from origins to outcomes.

Accepted version
Peer-reviewed

Type

Article

Change log

Authors

Green, Anthony R 

Abstract

Substantial progress has been made in our understanding of the pathogenetic basis of myeloproliferative neoplasms. The discovery of mutations in JAK2 over a decade ago heralded a new age for patient care as a consequence of improved diagnosis and the development of therapeutic JAK inhibitors. The more recent identification of mutations in calreticulin brought with it a sense of completeness, with most patients with myeloproliferative neoplasm now having a biological basis for their excessive myeloproliferation. We are also beginning to understand the processes that lead to acquisition of somatic mutations and the factors that influence subsequent clonal expansion and emergence of disease. Extended genomic profiling has established a multitude of additional acquired mutations, particularly prevalent in myelofibrosis, where their presence carries prognostic implications. A major goal is to integrate genetic, clinical, and laboratory features to identify patients who share disease biology and clinical outcome, such that therapies, both existing and novel, can be better targeted.

Description

Keywords

Animals, DNA Mutational Analysis, Hematologic Neoplasms, Humans, Janus Kinase 2, Mutation, Myelopoiesis, Myeloproliferative Disorders, Protein Kinase Inhibitors

Journal Title

Hematology Am Soc Hematol Educ Program

Conference Name

Journal ISSN

1520-4391
1520-4383

Volume Title

2017

Publisher

American Society of Hematology
Sponsorship
Cancer Research UK (21762)
Cancer Research UK (23917)